HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors

Clinical Cancer Research

Volumn 16, Issue 2, 2010, Pages 474-485

  Ahmed, Nabil ^a,b   Salsman, Vita S ^a,b   Kew, Yvonne ^c   Shaffer, Donald ^a,b   Powell, Suzanne ^c   Zhang, Yi J ^c   Grossman, Robert G ^c   Heslop, Helen E ^a,b   Gottschalk, Stephen ^a,b  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; INTERLEUKIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CELL SECRETION; CLINICAL ARTICLE; CONTROLLED STUDY; GLIOBLASTOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEM CELL; T LYMPHOCYTE; TUMOR REGRESSION; TUMOR XENOGRAFT;

ANIMALS; BRAIN NEOPLASMS; CELL CULTURE TECHNIQUES; CELLS, CULTURED; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MALE; MICE; MICE, INBRED ICR; MICE, SCID; NEOPLASMS, EXPERIMENTAL; NEOPLASTIC STEM CELLS; RECEPTOR, ERBB-2; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES, CYTOTOXIC; TUMOR BURDEN; TUMOR ESCAPE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 74549196076     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1322     Document Type: Article

References (48)

1. DeAngelis LM. Brain tumors. N Engl J Med 2001;344:114-23.
2. Buckner JC. Factors influencing survival in high-grade gliomas. Semin Oncol 2003;30:10-4.
3. Stupp R, Mason WP, Van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
4. Altaner C. Glioblastoma and stem cells. Neoplasma 2008;55:369-74.
5. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radio-resistance by preferential activation of the DNA damage response. Nature 2006;444:756-60.
6. Liau LM, Prins RM, Kiertscher SM, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 2005;11:5515-25.
7. Okada H, Lieberman FS, Walter KA, et al. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. J Transl Med 2007;5:67.
8. Schneider T, Gerhards R, Kirches E, Firsching R. Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme. J Neurooncol 2001;53:39-46.
9. Wheeler CJ, Black KL, Liu G, et al. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res 2008;68:5955-64.
10. Fine HA. Toward a glioblastoma vaccine: promise and potential pitfalls. J Clin Oncol 2004;22:4240-3.
11. Pule M, Finney H, Lawson A. Artificial T-cell receptors. Cytotherapy 2003;5:211-26.
12. Sadelain M, Riviere I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 2003;3:35-45.
13. Liu G, Ying H, Zeng G, et al. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Res 2004;64:4980-6.
14. Zhang JG, Eguchi J, Kruse CA, et al. Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics. Clin Cancer Res 2007;13:566-75.
15. Zhang JG, Kruse CA, Driggers L, et al. Tumor antigen precursor protein profiles of adult and pediatric brain tumors identify potential targets for immunotherapy. J Neurooncol 2008;88:65-76.
16. Ozaki M, Kishigami S, Yano R. Expression of receptors for neuregulins, ErbB2, ErbB3 and ErbB4, in developing mouse cerebellum. Neurosci Res 1998;30:351-4.
17. Gilbertson RJ, Pearson AD, Perry RH, Jaros E, Kelly PJ. Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma. Br J Cancer 1995;71:473-7.
18. Ahmed N, Salsman VS, Yvon E, et al. Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol Ther 2009;17:1779-87.
19. Ahmed N, Ratnayake M, Savoldo B, et al. Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res 2007;67:5957-64.
20. Gottschalk S, Ng CYC, Smith CA, et al. An Epstein-Barr virus deletion mutant that causes fatal lymphoproliferative disease unresponsive to virus-specific T cell therapy. Blood 2001;97:835-43.
21. Moritz D, Wels W, Mattern J, Groner B. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc Natl Acad Sci U S A 1994;91:4318-22.
22. Marras C, Mendola C, Legnani FG, DiMeco F. Immunotherapy and biological modifiers for the treatment of malignant brain tumors. Curr Opin Oncol 2003;15:204-8.
23. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314:126-9.
24. Park JR, Digiusto DL, Slovak M, et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 2007;15:825-33.
25. Till BG, Jensen MC, Wang J, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008;112:2261-71.
26. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008;14:1264-70.
27. Pule MA, Straathof KC, Dotti G, et al. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther 2005;12:933-41.
28. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M. Human Tlymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor. Nat Biotechnol 2002;20:70-5.
29. Carpenito C, Milone MC, Hassan R, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A 2009;106:3360-5.
30. Koka V, Potti A, Forseen SE, et al. Role of Her-2/neu overexpression and clinical determinants of early mortality in glioblastoma multiforme. Am J Clin Oncol 2003;26:332-5.
31. Hatano M, Eguchi J, Tatsumi T, et al. EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. Neoplasia 2005;7:717-22.
32. Bullain SS, Sahin A, Szentirmai O, et al. Genetically engineered T cells to target EGFRvIII expressing glioblastoma. J Neurooncol 2009;94:373-82.
33. Hernan R, Fasheh R, Calabrese C, et al. ERBB2 up-regulates S100A4 and several other prometastatic genes in medulloblastoma. Cancer Res 2003;63:140-8.
34. Lane HA, Beuvink I, Motoyama AB, et al. ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol 2000;20:3210-23.
35. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-8.
36. Jarboe JS, Johnson KR, Choi Y, Lonser RR, Park JK. Expression of interleukin-13 receptor α2 in glioblastoma multiforme: implications for targeted therapies. Cancer Res 2007;67:7983-6.
37. Saikali S, Avril T, Collet B, et al. Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Rα2, gp100 and TRP-2 for immunotherapy. J Neurooncol 2007;81:139-48.
38. + T cells against NY-ESO-1. N Engl J Med 2008;358:2698-703.
39. Sykulev Y, Joo M, Vturina I, Tsomides TJ, Eisen HN. Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity 1996;4:565-71.
40. Unanue ER, Harding CV, Luescher IF, Roof RW. Antigen-binding function of class II MHC molecules. Cold Spring Harb Symp Quant Biol 1989;54 Pt 1:383-92.
41. Bernhard H, Neudorfer J, Gebhard K, et al. Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer. Cancer Immunol Immunother 2008;57:271-80.
42. Disis M, Salazar LG, Coveler A, et al. Phase I study of infusion of HER2/neu (HER2) specific T cells in patients with advanced-stage HER2 overexpressing cancers who have received a HER2 vaccine. J Clin Oncol 2009;27:3000.
43. Mittendorf EA, Holmes JP, Ponniah S, Peoples GE. The E75 HER2/neu peptide vaccine. Cancer Immunol Immunother 2008;57:1511-21.
44. Glas M, Happold C, Rieger J, et al. Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. J Clin Oncol 2009;27:1257-61.
45. Tsuboi K, Saijo K, Ishikawa E, et al. Effects of local injection of ex vivo expanded autologous tumor-specific T lymphocytes in cases with recurrent malignant gliomas. Clin Cancer Res 2003;9:3294-302.
46. Plautz GE, Miller DW, Barnett GH, et al. T cell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Res 2000;6:2209-18.
47. Sloan AE, Dansey R, Zamorano L, et al. Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes. Neurosurg Focus 2000;9:e9.
48. Kahlon KS, Brown C, Cooper LJ, et al. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res 2004;64:9160-6.